J Neurocrit Care.  2024 Dec;17(2):41-48. 10.18700/jnc.240044.

Principle of intravenous fluid therapy in the neurocritically ill patients

• Ko SB

• KMID: 2563020
• DOI: http://doi.org/10.18700/jnc.240044

Abstract

Intravenous fluid therapy is a fundamental treatment in intensive care units (ICUs). Although most clinical trials have focused on patients requiring active resuscitation of the intravascular volume, such as those experiencing shock or sepsis, neurocritically ill patients may also benefit from intravenous fluid therapy during crises involving elevated intracranial pressure or reduced cerebral perfusion pressure. This review provides a comprehensive history of the evolution of intravenous fluid therapy, highlighting the development of crystalloids and the challenges associated with colloids. Previously favored for their theoretical advantages in sustaining intravascular volume, colloids have recently come under scrutiny due to safety concerns, including adverse renal outcomes. In contrast, crystalloids, particularly balanced crystalloids, are now preferred. Balanced crystalloids improve acid-base status and pose a lower risk of hyperchloremic metabolic acidosis than 0.9% saline. This review summarizes the key findings of recent clinical trials comparing the efficacy and safety profiles of crystalloids and colloids in ICU settings with a specific focus on neurocritical care populations.

Keyword

Intravenous Infusions; Fluid therapy; Crystalloid solutions; Colloids; Neurocritical care

Reference

1. Gordon D, Spiegel R. Fluid resuscitation: history, physiology, and modern fluid resuscitation strategies. Emerg Med Clin North Am. 2020; 38:783–93.

2. Lenggenhager-Krakoski NR, Bhakta P, Mandal M, Harmon D, O’Brien B. William Brooke O'Shaughnessy, an Irishman who introduced anaesthesia to India and brought eastern medicine to Britain. Br J Anaesth. 2023; 130:e451–3.

3. O’shaughnessy WB. Experiments on the blood in cholera. Lancet. 1831; 17:490.

4. O'Shaughnessy WB. Report on the chemical pathology of the malignant cholera. S. Highley; 1832.

5. Rivera AM, Strauss KW, van Zundert A, Mortier E. The history of peripheral intravenous catheters: how little plastic tubes revolutionized medicine. Acta Anaesthesiol Belg. 2005; 56:271–82.

6. Svensén C, Rodhe P. Intravascular volume replacement therapy. In: Hemmings HC, Egan TD, editors. Pharmacology and physiology for anesthesia. W.B. Saunders; 2013. p. 574-92.

7. Lunn KF, Johnson AS, James KM. Fluid therapy. In: Little SE, editor. The cat. W.B. Saunders; 2012. p. 52-89.

8. Wiedeman JE, Bowyer MW. Fluid therapy. In: Parsons PE, Wiener-Kronish JP, editors. Critical care secrets. 4th ed. Mosby; 2007. p. 35-8.

9. Bunn F, Trivedi D. Colloid solutions for fluid resuscitation. Cochrane Database Syst Rev 2012;(6):CD001319.

10. Cafferkey J, Ferguson A, Grahamslaw J, Oatey K, Norrie J, Lone N, et al. Albumin versus balanced crystalloid for resuscitation in the treatment of sepsis: a protocol for a randomised controlled feasibility study, “ABC-Sepsis”. J Intensive Care Soc. 2023; 24:78–84.

11. Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R, et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med. 2004; 350:2247–56.

12. SAFE Study Investigators; Australian and New Zealand Intensive Care Society Clinical Trials Group; Australian Red Cross Blood Service; George Institute for International Health, Myburgh J, Cooper DJ, et al. Saline or albumin for fluid resuscitation in patients with traumatic brain injury. N Engl J Med. 2007; 357:874–84.

13. Cooper DJ, Myburgh J, Heritier S, Finfer S, Bellomo R, Billot L, et al. Albumin resuscitation for traumatic brain injury: is intracranial hypertension the cause of increased mortality? J Neurotrauma. 2013; 30:512–8.

14. Jeffcote T, Ho KM. Associations between cerebrospinal fluid protein concentrations, serum albumin concentrations and intracranial pressure in neurotrauma and intracranial haemorrhage. Anaesth Intensive Care. 2010; 38:274–9.

15. Wiedermann CJ. Use of hyperoncotic human albumin solution in severe traumatic brain injury revisited: a narrative review and meta-analysis. J Clin Med. 2022; 11:2662.

16. Farag E, Traul D, George J, Ebrahim Z. 196 - Anesthesia for spine surgery and the prevention of complications. In: Steinmetz MP, Benzel EC, editors. Benzel's spine surgery. 4th ed. Elsevier; 2017. p. 1711-23.

17. Westphal M, James MF, Kozek-Langenecker S, Stocker R, Guidet B, Van Aken H. Hydroxyethyl starches: different products: different effects. Anesthesiology. 2009; 111:187–202.

18. Kozek-Langenecker SA. Effects of hydroxyethyl starch solutions on hemostasis. Anesthesiology. 2005; 103:654–60.

19. Kang D, Yoo KY. Fluid management in perioperative and critically ill patients. Acute Crit Care. 2019; 34:235–45.

20. Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med. 2008; 358:125–39.

21. Perner A, Haase N, Guttormsen AB, Tenhunen J, Klemenzson G, Åneman A, et al. Hydroxyethyl starch 130/0.42 versus Ringer’s acetate in severe sepsis. N Engl J Med. 2012; 367:124–34.

22. Myburgh JA, Finfer S, Bellomo R, Billot L, Cass A, Gattas D, et al. Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med. 2012; 367:1901–11.

23. U.S. Food and Drug Administration. Labeling changes on mortality, kidney injury, and excess bleeding with hydroxyethyl starch products [Internet]. U.S. Food and Drug Administration; 2021 [cited 2024 Dec 10]. Available from: https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/labeling-changes-mortality-kidney-injury-and-excess-bleeding-hydroxyethyl-starch-products.

24. European Medicines Agency. Hydroxyethyl starch - direct healthcare professional communication (DHPC) [Internet]. European Medicines Agency; 2024 [cited 2024 Dec 10]. Available from: https://www.ema.europa.eu/en/medicines/dhpc/hydroxyethyl-starch.

25. Lazarus-Barlow WS. On the initial rate of osmosis of blood-serum with reference to the composition of “physiological saline solution” in mammals. J Physiol. 1896; 20:145–57.

26. Hamburger HJ. A discourse on permeability in physiology and pathology. Lancet. 1921; 198:1039–45.

27. Semler MW, Kellum JA. Balanced crystalloid solutions. Am J Respir Crit Care Med. 2019; 199:952–60.

28. Ringer S. Concerning the influence exerted by each of the constituents of the blood on the contraction of the ventricle. J Physiol. 1882; 3:380–93.

29. Biswas S, McNerney P. Sydney ringer: the pipe water of new river water company and the discovery of the elixir of life [Internet]. American College of Surgeons; 2016 [cited 2024 Dec 10]. Available from: https://www.facs.org/media/xrmb5ntd/08_ringer.pdf.

30. Ringer S. A further contribution regarding the influence of the different constituents of the blood on the contraction of the heart. J Physiol. 1883; 4:29–42.3.

31. Lee JA. Sydney Ringer (1834-1910) and Alexis Hartmann (1898-1964). Anaesthesia. 1981; 36:1115–21.

32. Rizoli S. PlasmaLyte. J Trauma. 2011; 70(5 Suppl):S17–8.

33. Young P, Bailey M, Beasley R, Henderson S, Mackle D, McArthur C, et al. Effect of a buffered crystalloid solution vs saline on acute kidney injury among patients in the intensive care unit: the SPLIT Randomized Clinical Trial. JAMA. 2015; 314:1701–10.

34. Semler MW, Self WH, Wanderer JP, Ehrenfeld JM, Wang L, Byrne DW, et al. Balanced crystalloids versus saline in critically ill adults. N Engl J Med. 2018; 378:829–39.

35. Self WH, Semler MW, Wanderer JP, Wang L, Byrne DW, Collins SP, et al. Balanced crystalloids versus saline in noncritically ill adults. N Engl J Med. 2018; 378:819–28.

36. Zampieri FG, Machado FR, Biondi RS, Freitas FG, Veiga VC, Figueiredo RC, et al. Effect of intravenous fluid treatment with a balanced solution vs 0.9% saline solution on mortality in critically ill patients: the BaSICS Randomized Clinical Trial. JAMA. 2021; 326:1–12.

37. Finfer S, Micallef S, Hammond N, Navarra L, Bellomo R, Billot L, et al. Balanced multielectrolyte solution versus saline in critically ill adults. N Engl J Med. 2022; 386:815–26.

38. Hammond NE, Zampieri FG, Di Tanna GL, Garside T, Adigbli D, Cavalcanti AB, et al. Balanced crystalloids versus saline in critically ill adults: a systematic review with meta-analysis. NEJM Evid. 2022; 1:EVIDoa2100010.

39. Zampieri FG, Cavalcanti AB, Di Tanna GL, Damiani LP, Hammond NE, Machado FR, et al. Balanced crystalloids versus saline for critically ill patients (BEST-Living): a systematic review and individual patient data meta-analysis. Lancet Respir Med. 2024; 12:237–46.

40. Vallée M, Barthélémy I, Friciu M, Pelletier É, Forest JM, Benoit F, et al. Compatibility of lactated Ringer’s injection with 94 selected intravenous drugs during simulated Y-site administration. Hosp Pharm. 2021; 56:228–34.

41. Gin A, Walker S. Notice to hospitals regarding ceftriaxone-calcium incompatibility: what’s a clinician to do? Can J Hosp Pharm. 2009; 62:157–8.

42. Jurgens RW Jr, DeLuca PP, Papadimitriou D. Compatibility of amphotericin B with certain large-volume parenterals. Am J Hosp Pharm. 1981; 38:377–8.

43. Toporek AH, Semler MW, Self WH, Bernard GR, Wang L, Siew ED, et al. Balanced crystalloids versus saline in critically ill adults with hyperkalemia or acute kidney injury: secondary analysis of a clinical trial. Am J Respir Crit Care Med. 2021; 203:1322–5.

44. Potura E, Lindner G, Biesenbach P, Funk GC, Reiterer C, Kabon B, et al. An acetate-buffered balanced crystalloid versus 0.9% saline in patients with end-stage renal disease undergoing cadaveric renal transplantation: a prospective randomized controlled trial. Anesth Analg. 2015; 120:123–9.

45. Mistry AM. Which intravenous isotonic fluid offers better outcomes for patients with a brain injury? Neurocrit Care 2024 Oct 8 [Epub]. https://doi.org/10.1007/s12028-024-02139-3.

46. Mistry AM, Magarik JA, Feldman MJ, Wang L, Lindsell CJ, Fusco MR, et al. Saline versus balanced crystalloids for adults with aneurysmal subarachnoid hemorrhage: a subgroup analysis of the SMART Trial. Stroke Vasc Interv Neurol. 2022; 2:e000128.